Posts

SK Biopharmaceuticals Signs Up-to-$795 Million Biohaven Deal for Epilepsy Drug

on
SK Biopharmaceuticals has agreed to acquire exclusive global rights to Biohaven’s investigational epilepsy drug opakalim (BHV-7000), related Kv7 activators, and the underlying discovery platform. The agreement is valued at up to $795 million: $400 million in upfront cash—$350 million at closing and $50 million one year later—plus as much as $395 million in development and regulatory milestones. Royalties on future sales are additional. Opakalim is a selective Kv7.2/7.3 potassium-channel activator being tested in Phase 2/3 trials for focal-onset epilepsy. Biohaven will continue running the trials, while SK covers development costs. SK expects initial RISE3 trial results by the end of 2026, another data readout in 2028, and—if clinical and regulatory milestones are met—a U.S. launch as early as 2029 through SK Life Science. The deal strengthens SK’s neurology portfolio beyond its established epilepsy treatment cenobamate (XCOPRI). Opakalim remains investigational and is not gua...

FDA reportedly considers new technology and drugs deputy commissioner posts

on

FDA reportedly approves Revolution Medicines’ Rasonque for advanced pancreatic cancer

on

Akeso broadens ivonescimab ambitions after biliary tract cancer win

on

GOP lawmakers urge FDA to tighten scrutiny of Chinese clinical-trial data after reported deaths

on

Haisco Signs Potential $1.5B Sentivera Deal

on

AI in Cardiology: Now and the Road to 2035

on

Bausch + Lomb to pursue Phase 3 dry-eye trial despite Phase 2 endpoint miss

on

FDA approves Jazz’s Ziihera in frontline HER2-positive gastric cancer

on

McKesson to Acquire Precision Medicine Group for Approximately $2.25 Billion

on

4basebio and Genezen collaborate on synthetic DNA for viral-vector manufacturing

on

Will EU prescribers be swayed by AstraZeneca’s Etcamah case?

on

Telesis Bio’s Gibson SOLA targets faster AI-driven drug discovery

on